Hepatitis B Community
MYRCLUDEX B updates from int'l liver congress oral sessions
About This Community:

This forum is an un-mediated, patient-to-patient forum for questions and support regarding Hepatitis B. Topics in this forum include but are not limited to, Causes, Diagnosis, Family and Relationships, Living With Hepatitis B, Research Updates, Treatment, Success Stories, Support, Symptoms.

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

MYRCLUDEX B updates from int'l liver congress oral sessions

The antiviral study showed that all mice receiving Myrcludex-B remained negative for HDV and HBV serological and intrahepatic markers, whereas untreated mice became infected.way to go, this is the first drug that stops hbv by blocking hbsag in 100% of treated subjects. to note that in this experiment they used the new human mice which replicate what happens in human liver in vivo

Oral Presentations

Session Title: GENERAL SESSION 3 & AWARDS 2


Presentation Date: 02 APR, 2011

BLOCK OF HEPATITIS DELTA INFECTION BY THE ENTRY INHIBITOR MYRCLUDEX B IN UPA MICE: ESTABLISHMENT OF AN EFFICIENT MOUSE MODEL FOR HUMAN HBV/HDV INFECTION

M. Lutgehetmann1,2*, L.V. Mancke1, L. Allweiss1, T. Volz1, M. Helbig1, A.W. Lohse1, A. Alexandrov3, J. Petersen4, S. Urban5, M. Dandri1
1Department of Internal Medicine, 2Department of Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, 3Vision 7 GMBH, Frankfurt, 4IFI Institute for Interdisciplinary Medicine at Asklepios Clinic St. Georg, Hamburg, 5Department of Infectious Diseases, Molecular Virology, University Hospital Heidelberg, Heidelberg, Germany. *m.***@****


Hepatitis delta virus (HDV) is a subviral agent which can cause severe liver disease in association with hepatitis B virus (HBV). To date no HDV-specific antiviral drugs are available and interferon alpha remains the only treatment option. Establishment of more suitable HDV infection models may improve our understanding of the HDV replication mechanisms and permit in vivo preclinical antiviral drug evaluations.
Aim of the study was to use uPA/SCID mice repopulated with primary human hepatocytes to establish de novo HDV infection and to test the ability of an HBV envelope-derived entry inhibitor (Myrcludex-B) to prevent HDV infection in vivo.
Methods: Naïve and chronically HBV infected humanized mice were inoculated with a patient-derived serum containing 10E6 HDV-RNA (genotype1) and 10E8 HBV-DNA genome equivalents. Serological and intrahepatic HBV (rcDNA, cccDNA) and HDV-RNA levels were determined by quantitative RT-PCR over time. Presence of HBsAg, HBcAg and delta-Ag was ascertained by immunohistochemistry. Myrcludex-B, a novel entry inhibitor for HBV in preclinical tests was injected (2mg/kg daily) 1h before infection and in the following 4 days in 3/6 mice.
Results: Establishment of HDV infection was highly efficient both in HBV-infected and naïve chimeric mice (7/7 and 13/13, respectively). In HDV super-infected mice, delta-Ag positive human hepatocytes were detected already at 2 weeks post-infection (p.i), whereas the increase of HDV-positive cells demonstrated spreading of infection among human hepatocytes. In the setting of HBV/HDV simultaneous infection, HDV viremia reached peak levels between 6-8 weeks p.i. (up to 5*10^8 copies HDV/ml), while the peak of HBV viremia was detected 10 weeks p.i. Since a great majority of human hepatocytes stained delta-Ag-positive long before HBV spreading was completed, these in vivo studies confirmed that HDV can replicate intrahepatically in the absence of HBV. The antiviral study showed that all mice receiving Myrcludex-B remained negative for HDV and HBV serological and intrahepatic markers, whereas untreated mice became infected.
Conclusions:
i) We established an efficient model of chronic HBV/HDV infection for the study of HDV and for preclinical antiviral drug evaluations.
ii) We could demonstrate that HBV entry inhibitors can completely block de-novo HDV infection of human hepatocytes in vivo.
Related Discussions
11 Comments Post a Comment
Blank
Avatar_n_tn
Thanks for following up on this. Let's hope someday we can fight back this cruel disease.
Blank
Avatar_m_tn
Any update on clinical trial of this?
Blank
Avatar_m_tn
Phase I just started.
Phase II is scheduled for 2012.

http://www.life-sciences-germany.com/product/myrcludex-myr-gmbh-virostatic-agent-anti-infective-drug-2001-21242.html
Blank
Avatar_m_tn
i hope this becomes available soon
Blank
Avatar_m_tn
I guess this might take at least another 5 years but then you never know. Since the clinical studies take part close to my hometown I just applied (via Email) to get into. I will keep you informed about the outcome.....
Blank
Avatar_m_tn
Thanks! do keep us informed :)
Blank
Avatar_m_tn
Got an answer: At the moment they are justig testing it with healthy people. The efficacy studies are supposed to start after that (scheduled for 2012).  They also test on people with hep b then and told me to come back to them which I will.....
Blank
Avatar_m_tn
I keep having this wondering. Why they can't test the safety and efficacy at the same time.
Blank
Avatar_f_tn
when it is going to be available for us?
Blank
Avatar_m_tn
nobody knows because it just blocks reinfection so it can have a result only in combo with antivirals and peginterferon.
first trials in combo with antivirals ended last year,  since no publication bad results

we know that the dose needed to work makes sides so they are now using low doses but they probably dont work
Blank
Avatar_m_tn
hopefully they will get better results in combo with peg
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Emotional Eating Control: How to St...
Aug 28 by Roger Gould, M.D.Blank
233488_tn?1310696703
Blank
New Cannabis Article from NORTH Mag...
Jul 20 by John C Hagan III, MD, FACS, FAAOBlank
Top Hepatitis Answerers
Avatar_m_tn
Blank
stef2011
Italy
Avatar_m_tn
Blank
StephenCastlecrag
Australia
Avatar_m_tn
Blank
veteranB
CA
7951432_tn?1400922437
Blank
flyinsky
paris, France
Avatar_m_tn
Blank
makeadifferencenow
Avatar_m_tn
Blank
andrey19
Russia